Literature DB >> 27173589

Doxorubicin and cisplatin induce apoptosis in ovarian stromal cells obtained from cryopreserved human ovarian tissue.

Raffaella Fabbri1, Maria Macciocca1, Rossella Vicenti1, Roberto Paradisi1, Francesca Gioia Klinger2, Gianandrea Pasquinelli3, Enzo Spisni4, Renato Seracchioli1, Alessio Papi4.   

Abstract

AIM: To investigate mechanisms by which doxorubicin (DOX) and cisplatin (CIS) cause human ovarian stroma injury. PATIENTS &
METHODS: Stromal cells from human cryopreserved ovarian tissue were cultured in the presence of 1 µM DOX and 10 µM CIS. Ovarian damage induced by treatments was evaluated by 'Live/Dead' and sulforhodamine-B assays, the expression of different apoptosis markers.
RESULTS: Stromal cell growth was inhibited by DOX and CIS, and this effect was accompanied by apoptosis through mitochondrial pathway activation: Bax, cleaved-caspase 9, cleaved-PARP1 induction and Akt1, Bcl2, phospho-44/42-MAPK/ERK1/2 reduction were observed.
CONCLUSION: DOX and CIS induced apoptosis in human ovarian stromal cells. Knowledge of mechanisms by which the drugs act is important to identify possible ways to counteract side effects of chemotherapy on ovaries.

Entities:  

Keywords:  cisplatin; doxorubicin; human ovarian stromal cells

Mesh:

Substances:

Year:  2016        PMID: 27173589     DOI: 10.2217/fon-2016-0032

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  8 in total

Review 1.  Can Some Anticancer Treatments Preserve the Ovarian Reserve?

Authors:  Nicolas Vallet; Nicolas Boissel; Elisabeth Elefant; Florian Chevillon; Hélène Pasquer; Charlotte Calvo; Nathalie Dhedin; Catherine Poirot
Journal:  Oncologist       Date:  2021-01-29

2.  Possibility of women treated with fertility-sparing surgery for non-epithelial ovarian tumors to safely and successfully become pregnant-a Chinese retrospective cohort study among 148 cases.

Authors:  Bin Yang; Yan Yu; Jing Chen; Yan Zhang; Ye Yin; Nan Yu; Ge Chen; Shifei Zhu; Haiyan Huang; Yongqun Yuan; Jihui Ai; Xinyu Wang; Kezhen Li
Journal:  Front Med       Date:  2017-12-07       Impact factor: 4.592

3.  Differential pro-apoptotic effects of synthetic 4-thiazolidinone derivative Les-3288, doxorubicin and temozolomide in human glioma U251 cells.

Authors:  Lesya I Коbylinska; Olga Yu Klyuchivska; Iryna I Grytsyna; Natalia Finiuk; Rostyslav R Panchuk; Marina O Starykovych; Lilya Lehka; Roman B Lesyk; Borys S Zіmenkovsky; Rostyslav S Stoika
Journal:  Croat Med J       Date:  2017-04-14       Impact factor: 1.351

4.  The promise of Immuno-oncology: implications for defining the value of cancer treatment.

Authors:  Howard L Kaufman; Michael B Atkins; Prasun Subedi; James Wu; James Chambers; T Joseph Mattingly; Jonathan D Campbell; Jeff Allen; Andrea E Ferris; Richard L Schilsky; Daniel Danielson; J Leonard Lichtenfeld; Linda House; Wendy K D Selig
Journal:  J Immunother Cancer       Date:  2019-05-17       Impact factor: 13.751

5.  Epigallocatechin-3-gallate inhibits doxorubicin-induced inflammation on human ovarian tissue.

Authors:  R Fabbri; M Macciocca; R Vicenti; G Caprara; M P Piccinni; R Paradisi; P Terzano; A Papi; R Seracchioli
Journal:  Biosci Rep       Date:  2019-05-14       Impact factor: 3.840

6.  Impact of first-line cancer treatment on the follicle quality in cryopreserved ovarian samples from girls and young women.

Authors:  Valentina Pampanini; Magdalena Wagner; Babak Asadi-Azarbaijani; Irma C Oskam; Mona Sheikhi; Marcus O D Sjödin; Johan Lindberg; Outi Hovatta; Lena Sahlin; Richelle D Björvang; Marjut Otala; Pauliina Damdimopoulou; Kirsi Jahnukainen
Journal:  Hum Reprod       Date:  2019-09-29       Impact factor: 6.918

7.  Layer-by-layer pH-sensitive nanoparticles for drug delivery and controlled release with improved therapeutic efficacy in vivo.

Authors:  Wanfu Men; Peiyao Zhu; Siyuan Dong; Wenke Liu; Kun Zhou; Yu Bai; Xiangli Liu; Shulei Gong; Shuguang Zhang
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

Review 8.  Plant-Produced Monoclonal Antibody as Immunotherapy for Cancer.

Authors:  Meher Un Nessa; Md Atiar Rahman; Yearul Kabir
Journal:  Biomed Res Int       Date:  2020-08-24       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.